Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Ascendis Pharma A/S
  6. Summary
    ASND   US04351P1012

ASCENDIS PHARMA A/S

(ASND)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/10/2022 01/11/2022 01/12/2022 01/13/2022 01/14/2022 Date
116.18(c) 118.88(c) 121.85(c) 119.05(c) 122.96(c) Last
281 616 205 053 245 105 488 208 246 404 Volume
-0.58% +2.32% +2.50% -2.30% +3.28% Change
More quotes
Estimated financial data (e)
Sales 2021 7,59 M 8,67 M 8,67 M
Net income 2021 -403 M -460 M -460 M
Net cash position 2021 677 M 773 M 773 M
P/E ratio 2021 -14,6x
Yield 2021 -
Sales 2022 64,0 M 73,1 M 73,1 M
Net income 2022 -474 M -542 M -542 M
Net cash position 2022 475 M 542 M 542 M
P/E ratio 2022 -13,1x
Yield 2022 -
Capitalization 6 121 M 6 986 M 6 986 M
EV / Sales 2021 717x
EV / Sales 2022 88,2x
Nbr of Employees 482
Free-Float 10,5%
More Financials
Company
ASCENDIS PHARMA A/S is a Danish-based biopharmaceutical company, which is involved in manufacture products for rare diseases. The Company utilizes its TransCon technologies for treatment, which can be applied to existing drug therapies, including proteins, peptides and small molecules, to create prodrugs. The Company is headquartered in Copenhagen, Denmark with offices in Heidelberg, Germany and Palo Alto,... 
Read more
More about the company
Ratings of Ascendis Pharma A/S
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about ASCENDIS PHARMA A/S
01/13Wedbush Raises Price Target for Ascendis Pharma A/S to $189 From $186 on EU Approval fo..
MT
01/13Ascendis Pharma's Growth Hormone Drug TransCon hGH Gets EU Approval
MT
01/13Ascendis Pharma A/S Receives European Approval for TransCon™ hGH for Pediatric Gr..
AQ
01/13Ascendis Pharma A/S Receives European Approval for TransCon™ hGH for Pediatric Gro..
CI
01/13Wedbush Cuts Ascendis Pharma's PT to $186 From $191 on Skytrofa Contraindication for PW..
MT
01/11European ADRs Nudge Lower in Tuesday Trading
MT
01/10Ascendis Pharma A/S Provides Update on Vision 3x3 Strategic Roadmap at 40th Annual J.P...
AQ
01/06European ADRs Move Higher in Thursday Trading
MT
01/06Cowen Starts Ascendis Pharma at Market Perform With $136 Price Target
MT
01/05European ADRs Move Higher in Wednesday Trading
MT
01/04Ascendis Pharma A/S to Participate in 40th Annual J.P. Morgan Healthcare Conference
GL
2021Ascendis Pharma A/S Virtual R&D Program Update Highlights Continued Development Across ..
AQ
2021Ascendis Pharma A/S to Provide an Update on Two of Its Investigational Endocrinology Ra..
CI
2021Wells Fargo Starts Ascendis Pharma at Overweight With $176 Price Target
MT
2021Ascendis Pharma A/S to Host Virtual R&D Program Update on December 14
GL
More news
News in other languages on ASCENDIS PHARMA A/S
01/13Ascendis Pharma A/S reçoit l'approbation européenne de TransCon hGH pour le déficit en ..
01/11Les ADR européens en baisse dans les échanges de mardi
01/06Les ADR européens sont en hausse jeudi
01/05Les ADR européens sont en hausse mercredi
2021Les ADR européens en forte baisse dans la négociation de vendredi
More news
Analyst Recommendations on ASCENDIS PHARMA A/S
More recommendations
Chart ASCENDIS PHARMA A/S
Duration : Period :
Ascendis Pharma A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASCENDIS PHARMA A/S
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Last Close Price 107,73 €
Average target price 165,96 €
Spread / Average Target 54,1%
EPS Revisions
Managers and Directors
Jan Møller Mikkelsen President, CEO & Executive Director
Scott Thomas Smith Chief Financial Officer & Senior Vice President
Albert Cha Chairman
Birgitte Volck SVP, Head-Clinical Development & Medical Affairs
Kennett Sprogøe Senior Vice President, Head-Innovation & Research
Sector and Competitors
1st jan.Capi. (M$)
ASCENDIS PHARMA A/S-8.60%6 986
GILEAD SCIENCES, INC.-1.16%90 027
REGENERON PHARMACEUTICALS-2.58%64 327
VERTEX PHARMACEUTICALS6.58%59 510
WUXI APPTEC CO., LTD.-3.88%52 722
BIONTECH SE-23.97%47 338